Fmoc-Cit-PABA is a peptide linker useful for drug conjugate synthesis or ADC synthesis.

SU-5616 is a biochemical reagent. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation.

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC50 value of 88 nM. KWCN-41, specifically inhibiting cell necroptosis but not apoptosis, protects cell survival by blocking the necroptotic pathway, which inhibits the phosphorylation of essential proteins of the necroptosis. It also prevented the development of inflammation and reduced the level of inflammatory factors in mice. KWCN-41 is expected to be a lead compound for further studies in inflammatory diseases.

TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity.

ZM-226600 is a potent Kir6 (KATP) channel opener (EC50 = 0.5 μM), devoid of antiandrogen properties. ZM226600 is more active than oxybutynin in reducing bladder overactivity, and it is devoid of vascular side effects observed with pinacidil. Its short duration of action (about 1 h) is probably the main problem to solve, in order to consider this compound a valid alternative to antimuscarinics in the therapy of bladder overactivity.

A-674563 is a potent and selective Akt1 inhibitor with Ki of 11 nM. A-674563 suppressed the activation of the NLRP3 inflammasome in cardiomyocytes following β-adrenoceptor activation, suggesting that AKT1 is a critical regulator molecule upstream of the NLRP3 inflammasome. A-674563 suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206

C12-TLRa is an adjuvant lipidoid. C12-TLRa substitution can enhance the immunogenicity of clinically relevant SARS-CoV-2 mRNA-LNP vaccines, which holds translational potential.

Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors.

Lirafugratinib (RLY-4008) is an orally active and selective inhibitor of FGFR2.

CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

MEHP (Phthalic acid mono-2-ethylexyl ester) is a competitive inhibitor of CYP2C9 with IC50 of 6.37 μM.

TP-1454 is an activator of PKM2 with AC50 of 10 Nm in biochemical assays.TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells.

DOG-IM4 is an ionizable cationic lipid (apparent pKa = 5.6) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA.1 Immunization with LNPs containing DOG-IM4 and encapsulating mRNA encoding influenza A hemagglutinin (HA) increases HA-inhibiting antibody titers (HI titers) in mice and cynomolgus macaques.

ALC-0315 analgous-3 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.

BP Lipid 101 is an amino ionizable lipid analogous to SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 position relative to the amine nitrogen. The primary lipid tail has 7 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 102 is an ionizable lipid used to prepare lipid nanoparitlcels (LNPs). The lipid has ethanolamine as a lipid head group which enhances the mRNA encapsulation and provides exceptional physiochemical properties. Both esters of the lipid are at the C6 position relative to the amine. The lipid can be used for mRNA delivery. Reagent grade, for research purpose.

BP Lipid 103 is an amine ionizable lipid analogous to SM-102. The ethanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research only.

BP Lipid 104 is an ionizable lipid with ethanolamine head to enhance mRNA encapsulation. Ester linkages at C7 position relative to amine are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 105 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds, located at C7 relative to amine nitrogen, improve tissue clearance. Reagent grade, for research purpose.

BP Lipid 106 is an amino ionizable lipid with ester bonds located at C7 relative to nitrogen. The ethanolamine head can effectively enhance mRNA encapsulation while ester bonds improve tissue clearance. The primary lipid tail contains 11 carbons. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 107 is an ionizable amino lipid with both ester linkages located at C8 position relative to nitrogen amine. There is 7 carbons chain on the primary ester lipid tail. The secondary ester is introduced to improve protein expression. Reagent grade, for research purpose.

MS78 is the first p53Y220C AceTAC which recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant with little toxicity in cancer cells with wild-type p53.